论文信息 - Medicinal chemistry of cannabinoids

Medicinal chemistry of cannabinoids

The endocannabinoid system comprises the two well characterized Gi/o‐protein coupled receptors (cannabinoid receptor 1 (CB1) and CB2), their endogenous lipid ligands, and the enzymes involved in their biosynthesis and biotransformation. Drug discovery efforts relating to the endocannabinoid system have been focused mainly on the two cannabinoid receptors and the two endocannabinoid deactivating enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGL). This review provides an overview of cannabinergic agents used in drug research and those being explored clinically.

V Kiran Vemuri | A Makriyannis | V. K. Vemuri | A. Makriyannis | V. Vemuri

[1] R. Rapaka,et al. The medicinal chemistry of cannabinoids: an overview. , 1987, NIDA research monograph.

[2] 石井朝子,et al. 思春期における外傷後ストレス障害 : PTSD : Posttraumatic Stress Disorder , 2002 .

[3] Marilyn A Huestis,et al. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. , 2014, Drug and alcohol dependence.

[4] R. S. Stainton,et al. OR—a personal perspective , 2010, J. Oper. Res. Soc..

[5] P. Mahadevan,et al. An overview , 2007, Journal of Biosciences.

[6] Alexandros Makriyannis,et al. Latest advances in cannabinoid receptor agonists , 2009, Expert opinion on therapeutic patents.

[7] A. Makriyannis. 2012 Division of medicinal chemistry award address. Trekking the cannabinoid road: a personal perspective. , 2014, Journal of medicinal chemistry.

[8] W. Raub. From the National Institutes of Health. , 1990, JAMA.

[9] Paul R. Lehman. A Personal Perspective , 2002 .

[10] K. Mackie,et al. Programming of neural cells by (endo)cannabinoids: from physiological rules to emerging therapies , 2014, Nature Reviews Neuroscience.